Ekso Bionics Holdings, Inc. (EKSO) Stock Rating Lowered by Zacks Investment Research
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Monday.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Shares of Ekso Bionics Holdings (EKSO) traded up $0.48 during mid-day trading on Monday, reaching $1.53. 7,538,300 shares of the company’s stock were exchanged, compared to its average volume of 528,927. The company has a quick ratio of 5.73, a current ratio of 6.09 and a debt-to-equity ratio of 0.18. Ekso Bionics Holdings has a 12-month low of $0.99 and a 12-month high of $4.90.
Ekso Bionics Holdings (NASDAQ:EKSO) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). The firm had revenue of $1.60 million during the quarter, compared to analyst estimates of $2.40 million. Ekso Bionics Holdings had a negative net margin of 343.53% and a negative return on equity of 323.00%. equities research analysts predict that Ekso Bionics Holdings will post -0.81 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Ekso Bionics Holdings, Inc. (EKSO) Stock Rating Lowered by Zacks Investment Research” was reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/11/13/ekso-bionics-holdings-inc-ekso-stock-rating-lowered-by-zacks-investment-research.html.
In other news, insider Russ Angold sold 28,254 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $1.53, for a total transaction of $43,228.62. Following the completion of the sale, the insider now owns 250,678 shares in the company, valued at approximately $383,537.34. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last quarter, insiders acquired 41,264 shares of company stock valued at $48,255 and sold 259,352 shares valued at $399,373. Company insiders own 7.10% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of EKSO. Carl Domino Inc lifted its stake in shares of Ekso Bionics Holdings by 74.7% during the 2nd quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock worth $190,000 after buying an additional 35,088 shares during the last quarter. National Planning Corp lifted its stake in shares of Ekso Bionics Holdings by 116.2% during the 2nd quarter. National Planning Corp now owns 234,450 shares of the company’s stock worth $537,000 after buying an additional 126,000 shares during the last quarter. Vanguard Group Inc. raised its stake in Ekso Bionics Holdings by 32.9% in the 2nd quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock worth $1,650,000 after purchasing an additional 176,197 shares in the last quarter. Finally, Intellectus Partners LLC raised its stake in Ekso Bionics Holdings by 5.3% in the 2nd quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock worth $244,000 after purchasing an additional 5,294 shares in the last quarter. Institutional investors own 2.85% of the company’s stock.
About Ekso Bionics Holdings
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.